Lilly drops BACE inhibitors for Alzheimer’s

Eli Lilly and Co. (NYSE:LLY) discontinued the combination arm evaluating anti-β-amyloid mAb LY3002813 plus BACE inhibitor LY3202626 in the Phase II TRAILBLAZER-ALZ trial to treat Alzheimer's disease. Spokesperson Nicole Herbert told BioCentury that Lilly has discontinued development of LY3202626 as well as a separate β-site APP-cleaving enzyme 1 (BACE1) inhibitor that was in Phase I testing.

The double-blind, North American TRAILBLAZER-ALZ trial will continue to evaluate LY3002813 as monotherapy vs. placebo in patients with early symptomatic AD. Lilly disclosed the news in a pipeline update in its 3Q18 earnings presentation...